The clinical benefit response rate was 31% on 32 evaluable patients.
Thus, rather than focusing training programs on what to prepare and why, training should focus on how household preparedness can specifically benefit response professionals.
The primary endpoint was to assess clinical benefit response (complete or partial response, or stable disease for ≥ 16 weeks) following treatment with PF-04691502 or gedatolisib.
Both abnormalities in the distribution of B cells subsets and clinical benefit response to B cell depletion in autoimmune diseases, highlight their pivotal function.
Both abnormalities in the distribution of B cells subsets and clinical benefit response to B cell depletion in autoimmune states illustrate their importance.
Gemcitabine, 2′,2′-difluoro-2′-deoxycytidine, remains the standard of use and has more significant clinical benefit than fluorouracil (5-FU) (clinical benefit response, 23.8% of gemcitabine treated patients vs. 4.8% of 5-FU-treated patients, p = 0.0022) [1, 2].
Both abnormalities in the distribution of B cells subsets and clinical benefit response to B cell depletion in autoimmune diseases, including systemic lupus erythematosus (SLE), highlight their pivotal function.
Clinical benefit response was observed in 17/31 patients (54.8%).
All patients with clinical benefit response received ridaforolimus for more than 4 months.
Clinical benefit response, as introduced by Burris, was not measured prospectively in this study.
Manageable toxicity and good clinical benefit response rate were also important valuable findings of this trial.
